OBJECTIVES: To examine insulin regimens and factors that affect glycaemic control at 6 months after initiation of insulin therapy in patients with type 2 diabetes mellitus. RESEARCH DESIGN AND METHODS: Information on patients requiring insulin initiation as part of usual care was collected in a prospective, observational, open-label study in five European countries. Univariate and multiple regression analyses were used to investigate factors associated with HbA1c achieved at 6 months. RESULTS: Mean HbA1c for all patients at baseline was 9.6 ± 1.8%. Long/intermediate-acting insulin only was most commonly initiated in France and Spain, while long/intermediate or pre-mixed formulations were initiated in Greece and UK. This was consistent with guidelines used in those countries and there was little change in insulin regimen at 6 months in these countries. In Germany, short-acting insulin only was favoured at baseline and there was a shift towards basal/bolus regimens at 6 months, which reflected the local guidelines for insulin initiation in Germany. Mean HbA1c reduction was greatest in Germany (-2.3%), which was the only country to achieve a mean of <7% at 6 months. In all countries, HbA1c achieved at 6 months was associated with baseline HbA1c. Differences between countries were seen for influence of factors such as BMI, duration of diabetes, insulin regimen, insulin dose and number of oral anti-diabetes drugs on HbA1c achieved. Explained variability for the factors ranged from 5.6% to 22.9%. CONCLUSIONS: Differences in insulin regimen were observed between countries, and appeared to reflect the guidelines and treatment regimens used.
OBJECTIVES: To examine insulin regimens and factors that affect glycaemic control at 6 months after initiation of insulin therapy in patients with type 2 diabetes mellitus. RESEARCH DESIGN AND METHODS: Information on patients requiring insulin initiation as part of usual care was collected in a prospective, observational, open-label study in five European countries. Univariate and multiple regression analyses were used to investigate factors associated with HbA1c achieved at 6 months. RESULTS: Mean HbA1c for all patients at baseline was 9.6 ± 1.8%. Long/intermediate-acting insulin only was most commonly initiated in France and Spain, while long/intermediate or pre-mixed formulations were initiated in Greece and UK. This was consistent with guidelines used in those countries and there was little change in insulin regimen at 6 months in these countries. In Germany, short-acting insulin only was favoured at baseline and there was a shift towards basal/bolus regimens at 6 months, which reflected the local guidelines for insulin initiation in Germany. Mean HbA1c reduction was greatest in Germany (-2.3%), which was the only country to achieve a mean of <7% at 6 months. In all countries, HbA1c achieved at 6 months was associated with baseline HbA1c. Differences between countries were seen for influence of factors such as BMI, duration of diabetes, insulin regimen, insulin dose and number of oral anti-diabetes drugs on HbA1c achieved. Explained variability for the factors ranged from 5.6% to 22.9%. CONCLUSIONS: Differences in insulin regimen were observed between countries, and appeared to reflect the guidelines and treatment regimens used.
Authors: Gregory A Nichols; Teresa M Kimes; Joyce B Harp; Tzuyung Doug Kou; Kimberly G Brodovicz Journal: Diabetes Care Date: 2012-01-25 Impact factor: 19.112
Authors: Stephen Jones; Conxa Castell; Albert Goday; Helen T Smith; Claudia Nicolay; Alexander Simpson; Carole Salaun-Martin Journal: Clinicoecon Outcomes Res Date: 2012-12-20
Authors: William H Polonsky; Joyce Arsenault; Lawrence Fisher; Pamela Kushner; Eden M Miller; Teresa L Pearson; Mariusz Tracz; Stewart Harris; Norbert Hermanns; Bernd-M Scholz; Robyn K Pollom; Magaly Perez-Nieves; Roy Daniel Pollom; Irene Hadjiyianni Journal: Int J Clin Pract Date: 2017-07-23 Impact factor: 2.503
Authors: Antonio Nicolucci; Antonio Ceriello; Paolo Di Bartolo; Antonella Corcos; Marco Orsini Federici Journal: Diabetes Ther Date: 2019-12-23 Impact factor: 2.945
Authors: Craig J Currie; Chris D Poole; Marc Evans; John R Peters; Christopher Ll Morgan Journal: J Clin Endocrinol Metab Date: 2013-01-31 Impact factor: 5.958
Authors: Andreas Liebl; Steven Jones; Alberto Goday; Marian Benroubi; Conxa Castell; Axel Haupt; Claudia Nicolay; Helen T Smith Journal: Diabetes Ther Date: 2012-08-28 Impact factor: 2.945